Table 3.
Generalized Estimating Equations With Logistic Regression Predicting Future Viral Load ≥20 Copies/mL by Tenofovir Diphosphate Concentration
| OR (95% CI) | P | aOR (95% CI) | P | |
|---|---|---|---|---|
| TFV-DP in DBS Concentration at Preceding Visit | ||||
| ≥1850 fmol/punch | Ref | Ref | ||
| 1250–1849 fmol/punch | 1.41 (.55–3.61) | .478 | 1.29 (.50–3.35) | .599 |
| 700–1249 fmol/punch | 1.60 (.64–4.02) | .318 | 1.50 (.59–3.82) | .391 |
| 350–699 fmol/punch | 4.51 (1.49–13.68) | .008 | 3.46 (1.11–10.84) | .033 |
| <350 fmol/punch | 49.79 (16.73–148.12) | <.0001 | 12.94 (3.59–46.61) | <.0001 |
| Age, years | .93 (.89–.97) | .001 | .96 (.90–1.01) | .131 |
| Duration on ART at time of VL, months | 1.10 (1.07–1.12) | <.0001 | .97 (.92–1.02) | .193 |
| Previous VL result, log10 copies/mL | 5.48 (3.34–9.00) | <.0001 | 2.46 (1.37–4.42) | .003 |
| Duration between DBS and VL specimens, months | 1.18 (1.06–1.32) | .002 | 1.16 (.97–1.39) | .110 |
N = 365 DBS and VL samples in 81 women.
Abbreviations: aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval; DBS, dried blood spot; OR, odds ratio; Ref, reference; TFV-DP, tenofovir diphosphate; VL, viral load.